|Biotech Due Diligence||
Product development updates from Medtronic and Boston Scientific, and price control decisions from India that could change device manufacturers' emerging market strategy.
Enjoy a new collection of tweets highlighting the latest scientific and medical papers driving the conversation.
Earnings updates, acquisition progress, and regulatory strategy in this week's reading list!
Product development news from $MDT and $JNJ, as well as detailed analysis of the $BCR acquisition by $BDX.
Medtronic Announces Most Advanced StealthStation(TM) for Neurosurgery
Press Release ($MDT)
Medtronic (MDT) Announces DCB Demonstrates Consistent Results in Two New Analyses of Complex PAD Patients
Street Insider ($MDT)
Johnson & Johnson lands $260m Defense Dept. contract for orthopedic devices
Brad Perriello, Mass Device ($JNJ)
Johnson & Johnson's Medical Device Business: What Investors Need to Know
Motley Fool ($JNJ)
Becton, Dickinson Acquires C. R. Bard: Why It Has Got Me Interested - Eventually
Seeking Alpha ($BDX)
Immuno-oncology (IO) combination therapy- why the angst? Part 1 - Part 2
Paul Rennert (Sugar Cone Biotech)
Alzheimer’s: Learning From a Legacy of Bitter Setbacks
What it takes to create the future
David Baltimore (Timmerman Report)
With Neuralink, Elon Musk Promises Human-to-Human Telepathy. Don’t Believe It
Antonio Regalado (MIT Technology Review)
The Cost of Not Taking Your Medicine
Jane Brody (New York Times)
Your support is greatly appreciated